Advice
On 1 April 2015, the marketing authorisation for BindRen was withdrawn at the request of the marketing authorisation holder. Please see link to the European Medicines Agency statement.
Medicine details
- Medicine name:
- colestilan (BindRen)
- SMC ID:
- 939/14
- Indication:
- Treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis.
- Pharmaceutical company
- Mitsubishi Pharma Europe Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- IRP
- Status
- Withdrawn
- Date advice published
- 09 February 2015